Partner Therapeutics CEO and leadership

Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Debasish Roychowdhury, MD is a medical oncologist/hematologist and a proven leader in the pharmaceutical and biotech industry with many years of patient care, academic research and teaching experience. He is the co-founder and CTO of Partner Therapeutics, a commercial biotech based in Lexington, MA. He has served as the CMO at Seragon and Ra Pharmaceuticals and served as a consultant for other biotech companies and academic centers. Prior to Seragon, Dr. Roychowdhury served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. Dr. Roychowdhury is a member of the Board of Directors for ImCheck Therapeutics, T-knife Biotechnology, Rgenta Therapeutics, Lytix Biopharma AS, and Fund+, serves on multiple scientific advisory boards and is on the faculty of the Department of Biological Engineering, MIT, Cambridge.

Dr. Roychowdhury trained at the All India Institute of Medical Sciences and University of California, San Francisco.

William M. McClements has led our Corporate Operations team since September 2011. Previously, Mr. McClements served as a member of the executive team for Integreon Managed Solutions, Inc., a global research and business services company, from May 2010 to September 2011. Before then, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, from 1987 to May 2010. From September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change Inc., a non-profit focused on creating national issue-based campaigns. Mr. McClements holds an M.B.A. from Harvard Business School and a B.A. from Williams College.

Edwin Rock is a Chief Medical Officer at Partner Therapeutics and is based in Lexington, Massachusetts. He has worked as Medical Director at GSK; Vice President at LEERINK SWANN & CO INC; and Vice President, Clinical Research at MACROGENICS INC. Edwin studied at Perelman School of Medicine at the University of Pennsylvania between 2002 and 2004, Harvard Medical School between 1998 and 2001, and Stanford University School of Medicine until 1993.

Senior Executive with substantial experience in corporate finance, strategic planning, project management and mergers and acquisitions

Prior to joining OncXerna, Colleen served as Partner Therapeutics’ Chief Development Officer and Head of Regulatory and Quality. Before her move to biotech, Colleen established a distinguished career at Eli Lilly and Company spanning 20 years in oncology drug development where she held leadership roles in global regulatory, and health outcomes. Colleen’s final role at Lilly was as Verzenio global product development leader where she combined innovation with speed and empowered her team to create and execute a development strategy that led to the approval and launch of Verzenio for metastatic breast cancer, as well as the first positive early stage breast cancer study for a CDK 4&6 inhibitor. She received her B.S. in Chemistry, B.S. in Pharmacy from Butler University and an MBA from Purdue’s Krannert School of Business in 2016.

Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Debasish Roychowdhury, MD is a medical oncologist/hematologist and a proven leader in the pharmaceutical and biotech industry with many years of patient care, academic research and teaching experience. He is the co-founder and CTO of Partner Therapeutics, a commercial biotech based in Lexington, MA. He has served as the CMO at Seragon and Ra Pharmaceuticals and served as a consultant for other biotech companies and academic centers. Prior to Seragon, Dr. Roychowdhury served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. Dr. Roychowdhury is a member of the Board of Directors for ImCheck Therapeutics, T-knife Biotechnology, Rgenta Therapeutics, Lytix Biopharma AS, and Fund+, serves on multiple scientific advisory boards and is on the faculty of the Department of Biological Engineering, MIT, Cambridge.

Dr. Roychowdhury trained at the All India Institute of Medical Sciences and University of California, San Francisco.

Bob serves as a director and the Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx, he served as a co-founder, CEO, president, and director of Merrimack and a director and CEO of Atlantic Biosciences. He has extensive experience in a complete range of capital transactions, capital raising, global business development, and organizational capability building. Bob earned his undergraduate degree from Stanford and his Masters in Public and Private Management at Yale.

Debasish Roychowdhury, MD is a medical oncologist/hematologist and a proven leader in the pharmaceutical and biotech industry with many years of patient care, academic research and teaching experience. He is the co-founder and CTO of Partner Therapeutics, a commercial biotech based in Lexington, MA. He has served as the CMO at Seragon and Ra Pharmaceuticals and served as a consultant for other biotech companies and academic centers. Prior to Seragon, Dr. Roychowdhury served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. Dr. Roychowdhury is a member of the Board of Directors for ImCheck Therapeutics, T-knife Biotechnology, Rgenta Therapeutics, Lytix Biopharma AS, and Fund+, serves on multiple scientific advisory boards and is on the faculty of the Department of Biological Engineering, MIT, Cambridge.

Dr. Roychowdhury trained at the All India Institute of Medical Sciences and University of California, San Francisco.